NutriBand (NTRB) Total Current Liabilities (2016 - 2026)
NutriBand (NTRB) posted Total Current Liabilities of $832137.0 for Q2 2026, up 6.1% sequentially from $784281.0 in Q1 2026, and down 10.04% YoY from $925051.0 in Q2 2025.
NutriBand (NTRB) Total Current Liabilities (2016 - 2026) Analysis & Trends
NutriBand has reported Total Current Liabilities for 11 years, with the latest figure at $832137.0 in Q2 2026.
- Quarterly Total Current Liabilities fell 10.04% year-over-year to $832137.0 in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $832137.0 (down 10.04% YoY) and the FY2026 annual result came in at $784281.0, down 20.2% from the prior year.
- Total Current Liabilities rose to $832137.0 in Q2 2026 per NTRB's latest filing, from $784281.0 in the prior quarter.
- Over five years, Total Current Liabilities peaked at $1.6 million in Q3 2025 and troughed at $717774.0 in Q4 2023.
- A 5-year average of $936492.7 and a median of $818030.5 in 2022 frame the typical range for Total Current Liabilities.
- The sharpest annual moves came in 2022 and 2024: Total Current Liabilities sank 71.33% in 2022, then surged 80.63% in 2024.
- Over 5 years, Total Current Liabilities stood at $789752.0 in 2022, then dropped by 9.11% to $717774.0 in 2023, then jumped by 73.84% to $1.2 million in 2024, then sank by 38.09% to $772524.0 in 2025, then gained by 7.72% to $832137.0 in 2026.
- According to Business Quant data, Total Current Liabilities over the past three periods registered $832137.0, $784281.0, and $772524.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.57 Bn | 130.72 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 77.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.00 Bn | 59.82 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 56.27 Bn | 51.13 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.00 Bn | 36.90 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.68 Bn | 9.29 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.43 Bn | 26.27 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.34 Bn | 26.51 Bn | - | 630.93 Mn |
| 10 | NutriBand | 54.82 Mn | 50.82 Mn | 196,801.00 | 832,137.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 832,137.00 |
| Jan 31, 2026 | 784,281.00 |
| Oct 31, 2025 | 772,524.00 |
| Jul 31, 2025 | 1.57 Mn |
| Apr 30, 2025 | 925,051.00 |
| Jan 31, 2025 | 982,845.00 |
| Oct 31, 2024 | 1.25 Mn |
| Jul 31, 2024 | 1.10 Mn |
| Apr 30, 2024 | 1.42 Mn |
| Jan 31, 2024 | 999,093.00 |
| Oct 31, 2023 | 717,774.00 |
| Jul 31, 2023 | 874,127.00 |
| Apr 30, 2023 | 784,393.00 |
| Jan 31, 2023 | 748,613.00 |
| Oct 31, 2022 | 789,752.00 |
| Jul 31, 2022 | 803,924.00 |
| Apr 30, 2022 | 723,057.00 |
| Jan 31, 2022 | 779,256.00 |
| Oct 31, 2021 | 1.00 Mn |
| Jul 31, 2021 | 2.66 Mn |